Asia
Advances in medical science has led to evolution in therapeutics and diagnostic process of diseases.
Demand for bioengineered protein drugs is on an upward rise as awareness regarding their success rate, safety, specificity, and bio-reactivity catches on with people.
With the acquisition of San Diego-based PvP Biologics and a recent deal with COUR Pharmaceuticals, Takeda Pharmaceutical is looking to become a world leader in the treatment of celiac disease and other gastrointestinal disorders.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
The agency has identified approximately 20 drugs whose active ingredients or finished products are solely sourced in China.
Three years after Takeda and San Diego-based PvP Biologics inked a $35 million deal to develop a novel treatment for celiac disease, the Japanese pharma company has exercised its option to acquire the company for $330 million.
Under the license deal, RedHill is paying AstraZeneca $52.5 million up front with another non-contingent payment of $15 million 18 months after the deal closes.
The most recent BioSpace Ideal Employer Report revealed the impact of team dynamics on employees within life sciences organizations.
Via a five-year collaborative research pact, Harvard and Guangzhou Institute will split $115 million in research funding provided by China Evergrande Group.
The U.S. Food and Drug Administration is compiling a list of drugs that are at risk of shortage if the outbreak in China continues to worsen.
PRESS RELEASES